ESMO 2018 | Upcoming IO combinations for advanced HCC
An influx of treatments are emerging against hepatocellular carcinoma (HCC), a common malignancy with huge unmet needs, says Michael Pishvaian, MD, PhD, of Georgetown University, Washington, WA, at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. Dr Pishvaian expresses excitement for the ongoing Phase III IMbrave150 trial (NCT03434379) comparing bevacizumab and atezolizumab vs. the first-line standard of care, sorafenib, as well as for multi-kinase and immune checkpoint inhibitor combination treatments. In the near future, Dr Pishvaian sees immunotherapy being established as first-line treatment for HCC.
Get great new content delivered to your inboxSign up